CELL-DYN Emerald Designed to Deliver Quick, Reliable Results for Small to
WASHINGTON, July 28 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) will preview an upcoming addition to the CELL-DYN(R) family of hematology instruments, the Emerald(TM), at the American Association of Clinical Chemistry (AACC) Annual Meeting this week. The Emerald is designed to be a valuable tool for performing complete blood counts (CBCs) -- a test frequently ordered by doctors to assess a patient's overall health and to screen for a variety of disorders such as anemia and infection. The Emerald has the ability to complete CBC results in 60 seconds and report results in easy-to-read histograms representing white blood cells, red blood cells and platelets.
Expected to be available in the United States by the end of the year, subject to regulatory clearance, the Emerald will expand Abbott's hematology platform by offering a premium, robust low-volume solution for small to mid-sized clinical laboratories. Enhanced technology combined with intuitive software and onboard reagents enable the Emerald to offer reliable performance while promoting faster and simpler data entry.
As low to medium-volume hospital laboratories and clinics continue to seek greater efficiency under tight space limitations, the Emerald is expected to deliver reliable, productivity-enhancing performance in a small footprint.
The AACC Annual Meeting is a global meeting that attracts nearly 20,000 attendees from more than 100 countries. The Emerald is on display in Abbott's AACC exhibit booth (No. 1507).
Abbott's CELL-DYN family of hematology instruments is well known for its efficiency and ability to provide fast access to patient results. Instruments range from larger analyzers that process a high number of patient samples to smaller instruments designed for medium and small-volume facilities. Besides supplying standard CBC results, some instruments have additional features to aid in the evaluation of more complex disease states or infections including cancer, HIV and a variety of anemias.
About Abbott's Diagnostics Businesses
Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 65,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. Abbott's history is filled with examples of first-of-a-kind diagnostic products and significant technological and research advancements.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.
Copyright©2008 PR Newswire.
All rights reserved